Transactions
18
Insider / HALOZYME THERAPEUTICS, INC.
LaBrosse Nicole
SVP, CHIEF FINANCIAL OFFICER at HALOZYME THERAPEUTICS, INC.
- Company
- HALOZYME THERAPEUTICS, INC.
- Ticker
- HALO
- First filing on record
- February 11, 2026
- Latest trade on record
- February 23, 2026
- SEC filings
- EDGAR ↗
LaBrosse Nicole, SVP, CHIEF FINANCIAL OFFICER at HALOZYME THERAPEUTICS, INC., has disclosed 18 transactions in HALO since February 11, 2026: 0 purchases (0 open-market buys) and 5 sales, worth about $1.5M at the reported prices. The latest was filed February 24, 2026, 1 day after the trade.
Open-market buys
0
Sales
5
Avg. disclosure lag
1.7d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months LaBrosse Nicole made no purchases and 5 sales worth $1.5M, plus 13 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
LaBrosse Nicole has traded 1 stock on record; the largest by dollars is HALO.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 3 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 10 | 71,586 | — |
| F | Shares withheld for tax | 5 | 19,378 | $1.5M |
| A | Grant or award | 3 | 42,117 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 18 | 0 | 5 · $1.5M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| HALO | Option / conversion M | February 23, 2026 | February 24, 2026 | 1d | 6,688 | — | — | derivative | Form 4 ↗ | |
| HALO | Option / conversion M | February 20, 2026 | February 24, 2026 | 4d | 5,332 | — | — | derivative | Form 4 ↗ | |
| HALO | Sell F | February 23, 2026 | February 24, 2026 | 1d | 3,608 | $71 | $255K | Form 4 ↗ | ||
| HALO | Option / conversion M | February 23, 2026 | February 24, 2026 | 1d | 6,688 | — | — | Form 4 ↗ | ||
| HALO | Sell F | February 20, 2026 | February 24, 2026 | 4d | 2,876 | $71 | $204K | Form 4 ↗ | ||
| HALO | Option / conversion M | February 20, 2026 | February 24, 2026 | 4d | 5,332 | — | — | Form 4 ↗ | ||
| HALO | Option / conversion M | February 16, 2026 | February 17, 2026 | 1d | 13,351 | — | — | derivative | Form 4 ↗ | |
| HALO | Option / conversion M | February 16, 2026 | February 17, 2026 | 1d | 5,329 | — | — | derivative | Form 4 ↗ | |
| HALO | Option / conversion M | February 16, 2026 | February 17, 2026 | 1d | 5,093 | — | — | derivative | Form 4 ↗ | |
| HALO | Sell F | February 16, 2026 | February 17, 2026 | 1d | 7,273 | $79 | $578K | Form 4 ↗ | ||
| HALO | Option / conversion M | February 16, 2026 | February 17, 2026 | 1d | 13,351 | — | — | Form 4 ↗ | ||
| HALO | Sell F | February 16, 2026 | February 17, 2026 | 1d | 2,874 | $79 | $228K | Form 4 ↗ | ||
| HALO | Option / conversion M | February 16, 2026 | February 17, 2026 | 1d | 5,329 | — | — | Form 4 ↗ | ||
| HALO | Sell F | February 16, 2026 | February 17, 2026 | 1d | 2,747 | $79 | $218K | Form 4 ↗ | ||
| HALO | Option / conversion M | February 16, 2026 | February 17, 2026 | 1d | 5,093 | — | — | Form 4 ↗ | ||
| HALO | Other A | February 9, 2026 | February 11, 2026 | 2d | 29,502 | — | — | derivative | Form 4 ↗ | |
| HALO | Other A | February 9, 2026 | February 11, 2026 | 2d | 7,448 | — | — | derivative | Form 4 ↗ | |
| HALO | Other A | February 9, 2026 | February 11, 2026 | 2d | 5,167 | — | — | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| February 24, 2026 | Form 4 | 0001159036-26-000029 | 6 | published | EDGAR ↗ |
| February 17, 2026 | Form 4 | 0001159036-26-000026 | 9 | published | EDGAR ↗ |
| February 11, 2026 | Form 4 | 0001159036-26-000015 | 3 | published | EDGAR ↗ |
Other insiders at HALOZYME THERAPEUTICS, INC.
- Torley Helen PRESIDENT AND CEO 182 rows
- Snyder Mark Howard SVP, CHIEF LEGAL OFFICER 23 rows
- Caudill Cortney SVP, CHIEF OPERATING OFFICER 19 rows
- Connaughton Bernadette Director 12 rows
- Posard Matthew L. Director 10 rows
- Daly James M Director 8 rows
- Henderson Jeffrey William Director 7 rows
- RAMSAY DAVID A Interim CFO 6 rows
- Krishnan Mahesh Director 5 rows
- Lang James Paul Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: HALOZYME THERAPEUTICS, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 3 | 18 | February 11, 2026 | February 24, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.